ElectroCore

electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa

Retrieved on: 
Tuesday, February 21, 2023
ECOR, TGA, SVP, Global Sales Law Project, Nerve conduction study, Kanimozhi NVN Somu, Patient, Health Canada, FDA, ElectroCore, Headache, Pharmaceutical industry, EU

ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with Byond Healthcare Pty Ltd. to serve as the exclusive distributor of gammaCore SapphireTM, non-invasive vagus nerve stimulator (nVNS) in South Africa and Namibia.

Key Points: 
  • ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with Byond Healthcare Pty Ltd. to serve as the exclusive distributor of gammaCore SapphireTM, non-invasive vagus nerve stimulator (nVNS) in South Africa and Namibia.
  • “Access to exceptional medical technologies is key to improving healthcare outcomes,” said David Loubser, Managing Director of Byond Healthcare Pty Ltd. “It is a privilege for Byond to provide clinicians in South Africa and Namibia with a cutting-edge, clinically proven tool that we believe can help combat the opioid crisis by treating a variety of pain conditions with a non-pharmaceutical therapeutic option.
  • “Byond’s focus on innovative pain management solutions makes them an ideal distributor for us as we take gammaCore into Africa nations for the first time.
  • This agreement helps us to mobilize the response to calls from patients and clinicians alike to make gammaCore available in South Africa and Namibia.”
    The initial term of the agreement is three years and contains customary terms and conditions, and regulatory clearances are required before sales and revenue can occur.

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

Retrieved on: 
Thursday, February 16, 2023
ECOR, Patent, Electrode, NVN, United States patent law, ADHD, 1836 U.S. Patent Office fire, Inflammation, Psychology, Emotional and behavioral disorders, Spectrum, Asperger syndrome, ElectroCore, Medicine, Attention deficit hyperactivity disorder predominantly inattentive, 3D printing, Pharmaceutical industry

ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents and intends to issue a third new patent related to its non-invasive vagus nerve stimulation (nVNS) technology to electroCore, including the following patents:

Key Points: 
  • ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents and intends to issue a third new patent related to its non-invasive vagus nerve stimulation (nVNS) technology to electroCore, including the following patents:
    U.S. Patent No.
  • “We are excited to broaden our intellectual property with the addition of these new patents” stated Dan Goldberger, Chief Executive Officer of electroCore.
  • “electroCore’s proven technology and expanding intellectual property highlights its use across a range of disorders and diseases.
  • We are excited to begin exploring the behavioral disorder space and the potential for nVNS in a post-operative setting.”

electroCore Completes Sale of New Jersey Tax Benefits

Retrieved on: 
Wednesday, February 15, 2023
Transfer, ECOR, Biotechnology, New Jersey Economic Development Authority, Sale, Research, NOL, Growth, ElectroCore, Life insurance

ROCKAWAY, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer program.

Key Points: 
  • ROCKAWAY, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer program.
  • As a result, the Company has received approximately $211,000 in non-dilutive cash from the sale of these net operating loss (NOL) tax benefits.
  • “We appreciate the support from the state of New Jersey through its NOL program, which we have benefited from over the past few years,” stated, Brian Posner, Chief Financial Officer of electroCore.
  • NOLs may be sold for at least 80 percent of their value, up to a maximum lifetime benefit of $20 million per business.

electroCore Announces Reverse Stock Split

Retrieved on: 
Tuesday, February 14, 2023
ECOR, Panel, CUSIP, Securities and Exchange Commission (Nigeria), Security (finance), BID, Hearing, ElectroCore, Cryptocurrency

ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-15.

Key Points: 
  • ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-15.
  • Following the reverse stock split, the new CUSIP number of the common stock will be 28531P202, with the par value per share of common stock remaining at $0.001.
  • When the reverse stock split becomes effective, every 15 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock.
  • Each stockholder’s percentage ownership interest in electroCore will remain unchanged after the reverse stock split (other than the de minimis impact from the elimination of the fractional shares).

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™

Retrieved on: 
Tuesday, December 20, 2022
ElectroCore, Vagus nerve stimulation, ECOR, Vagus nerve, Sleep, Learning, Memory

ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called TruvagaTM for customers residing in the United States.

Key Points: 
  • ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called TruvagaTM for customers residing in the United States.
  • The new wellness product is offered through our new ecommerce site, www.truvaga.com, and promotes general wellbeing.
  • Truvaga is a handheld non-invasive vagus nerve stimulator that utilizes our proven technology to quickly and gently activate the vagus nerve.
  • “The Truvaga product will allow customers to incorporate vagus nerve stimulation as part of a holistic approach to improving their wellbeing.”

electroCore Announces Issuance of Two New U.S. Patents

Retrieved on: 
Wednesday, December 7, 2022
Indigestion, A luta continua, Migraine, Neurology, Adolescence, Nerve conduction study, Patient, Hearing, NVN, Nature, Ear, Hypertension, Disclosure, Marketing, FDA, Medication overuse headache, Patent, Skin, Pain, Neck, Risk, Cluster headache, Gastroparesis, Magnetism, Tachycardia, Union, ElectroCore, Disorder, Ileus, Transcutaneous electrical nerve stimulation, IP, Indometacin, Bradycardia, ECOR, Safety, 1836 U.S. Patent Office fire, Headache, Hemicrania continua, Vagus nerve, Functional gastrointestinal disorder, Hypotension, Medical device, Pharmaceutical industry

11,511,109 entitled “Non-invasive Magnetic or Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and other Functional Gastrointestinal Disorders” issued on November 29, 2022.

Key Points: 
  • 11,511,109 entitled “Non-invasive Magnetic or Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and other Functional Gastrointestinal Disorders” issued on November 29, 2022.
  • This patent is generally related to methods for treating gastroparesis, functional dyspepsia and/or ileus with nVNS.
  • 11,517,742 entitled “Non-invasive Vagal Nerve Stimulation to Treat Disorders” issued on December 6, 2022.
  • “The issuance of these two new patents continues to broaden and strengthen the usage of our nVNS therapy across multiple indications and methods,” Dan Goldberger, Chief Executive Officer of electroCore.

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association

Retrieved on: 
Friday, November 18, 2022
COVID-19, Hypertension, Cluster headache, Medication overuse headache, Patient, IP, Skin, Adolescence, Vagus nerve, Bradycardia, Pharmacy, Indometacin, Nature, National Coding Week, Union, Pain, Safety, Overalls, Hemicrania continua, Neurology, Migraine, NVN, APB, Tachycardia, Transcutaneous electrical nerve stimulation, CNK, Senior, A luta continua, News, Hypotension, Nerve conduction study, Hearing, Sapphire, Headache, ElectroCore, ECOR, FDA, Pharmaceutical industry

CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout Belgium and enables product recognition throughout the pharmaceutical network.

Key Points: 
  • CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout Belgium and enables product recognition throughout the pharmaceutical network.
  • We have taken a big step forward in making our therapy more widely available throughout Europe.
  • The publication of the CNK code, makes gammaCore recognized within the Belgian pharmaceutical database and therefore available via any pharmacy in Belgium.
  • When placed on a patients neck over the vagus nerve, gammaCore stimulates the nerves afferent fibers, which may lead to a reduction of pain in patients.

electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum

Retrieved on: 
Monday, November 14, 2022
Migraine, Cluster headache, Indometacin, Canaccord Genuity, Diagnosis, ElectroCore, A luta continua, Neurology, Medtech, ECOR, Digital health, Retail, Pharmaceutical industry

ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCores Chief Executive Officer, Dan Goldberger, will be conducting one-on-ones at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum.

Key Points: 
  • ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCores Chief Executive Officer, Dan Goldberger, will be conducting one-on-ones at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum.
  • electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology.
  • The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

electroCore Announces Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Patient, Company, Migraine, Private Securities Litigation Reform Act, A luta continua, Skin, Cluster headache, Investment, Hearing, Time, Bradycardia, GAAP, NVN, Medication overuse headache, Headache, Neurology, Industry, Overalls, Indometacin, Hypotension, FDA, Adult, Webcast, Transcutaneous electrical nerve stimulation, EBITDA, Conference, Hypertension, Terminology, COVID-19, ElectroCore, Nature, Nerve conduction study, Research, Vagus nerve, Concussion, Safety, Tachycardia, Hemicrania continua, IP, Absorption, Union, Depreciation, SEC, Pain, Adolescence, Video game, Pharmaceutical industry

ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced third quarter 2022 financial results and provided an operational update.

Key Points: 
  • Gross margin for the third quarter of 2022 was 87%, compared to 76% in the third quarter of 2021.
  • Total operating expenses in the third quarter of 2022 were approximately $7.3 million, as compared to $5.1 million in the third quarter of 2021.
  • Research and development expense in the third quarter of 2022 was $1.6 million as compared to $470 thousand in the third quarter of 2021.
  • Selling, general and administrative expense in the third quarter of 2022 was $5.7 million as compared to $4.6 million in the third quarter of 2021.

electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC

Retrieved on: 
Tuesday, November 1, 2022
Migraine, Nature, Tachycardia, Hearing, Hypotension, Adult, Medication overuse headache, Cluster headache, Bradycardia, Pain, Partnership, SEC, GLOBE, Patient, Time, LLC, Hypertension, Industry, COVID-19, ECOR, Sapphire, ElectroCore, Nerve conduction study, Hemicrania continua, Overalls, NVN, Indometacin, Terminology, Technology, Vagus nerve, Private Securities Litigation Reform Act, FDA, Union, Skin, Neurology, Safety, Headache, Adolescence, A luta continua, Transcutaneous electrical nerve stimulation, Pharmaceutical industry

Joerns mission is to simplify care delivery so providers can focus on patients needs and payors can be confident that the best value-based therapies are available to their beneficiaries, said Doug Ferguson, Chief Strategy Officer at Joerns Healthcare.

Key Points: 
  • Joerns mission is to simplify care delivery so providers can focus on patients needs and payors can be confident that the best value-based therapies are available to their beneficiaries, said Doug Ferguson, Chief Strategy Officer at Joerns Healthcare.
  • We are excited to be working with Joerns as we expand patient access to our therapy, commentedDan Goldberger, Chief Executive Officer of electroCore.
  • Joerns Healthcare is a healthcare technology and equipment services company focused on driving the transformation of care nationally across the post-acute continuum.
  • We are simplifying the complex post-acute care world by providing the technology, professionals, products, and data to help streamline the process, so providers concentrate on care.